GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucid Diagnostics Inc (NAS:LUCD) » Definitions » EV-to-EBIT

Lucid Diagnostics (Lucid Diagnostics) EV-to-EBIT : -1.17 (As of May. 03, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lucid Diagnostics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Lucid Diagnostics's Enterprise Value is $61.27 Mil. Lucid Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-52.25 Mil. Therefore, Lucid Diagnostics's EV-to-EBIT for today is -1.17.

The historical rank and industry rank for Lucid Diagnostics's EV-to-EBIT or its related term are showing as below:

LUCD' s EV-to-EBIT Range Over the Past 10 Years
Min: -21.3   Med: -1.01   Max: -0.43
Current: -1.17

During the past 5 years, the highest EV-to-EBIT of Lucid Diagnostics was -0.43. The lowest was -21.30. And the median was -1.01.

LUCD's EV-to-EBIT is ranked worse than
100% of 461 companies
in the Medical Devices & Instruments industry
Industry Median: 20.01 vs LUCD: -1.17

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Lucid Diagnostics's Enterprise Value for the quarter that ended in Dec. 2023 was $74.67 Mil. Lucid Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-52.25 Mil. Lucid Diagnostics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -69.98%.


Lucid Diagnostics EV-to-EBIT Historical Data

The historical data trend for Lucid Diagnostics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucid Diagnostics EV-to-EBIT Chart

Lucid Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -4.88 -0.62 -1.43

Lucid Diagnostics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.62 -0.77 -0.93 -0.98 -1.43

Competitive Comparison of Lucid Diagnostics's EV-to-EBIT

For the Medical Devices subindustry, Lucid Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucid Diagnostics's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lucid Diagnostics's EV-to-EBIT falls into.



Lucid Diagnostics EV-to-EBIT Calculation

Lucid Diagnostics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=61.270/-52.25
=-1.17

Lucid Diagnostics's current Enterprise Value is $61.27 Mil.
Lucid Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-52.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lucid Diagnostics  (NAS:LUCD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Lucid Diagnostics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-52.25/74.669159
=-69.98 %

Lucid Diagnostics's Enterprise Value for the quarter that ended in Dec. 2023 was $74.67 Mil.
Lucid Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-52.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lucid Diagnostics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Lucid Diagnostics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Lucid Diagnostics (Lucid Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Executives
Stanley Lapidus director 101 HARTWELL AVE., LEXINGTON MA 02421
Debra White director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Michael Adam Gordon officer: General Counsel ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil officer: Chief Operating Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Pavmed Inc. 10 percent owner 360 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10017
Lishan Aklog director, officer: Chief Executive Officer 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Dennis M Mcgrath officer: Chief Financial Officer C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Ronald M Sparks director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
James L Cox director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Aster Angagaw director 150 PEABODY PLACE, MEMPHIS TN 38103
Jacque J Sokolov director
David F Wurtman officer: Chief Medical Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165